Con motivo del Día Internacional del Alzheimer, celebrado el 21 de septiembre, recopilamos las publicaciones científicas del programa TransNanoAvansens con investigaciones centradas en su diagnosis temprana.
En este año 2022, se han publicado dos nuevos artículos científicos en los que se presentan immunosensores electroquímicos para su diagnosis, en una de ellos han trabajado conjuntamente los grupos BIOUCM y MININANOALCALA, junto con el Instituto Carlos III,
G. Ozcelikay, M. Gamella, M. A. Unal, K. Gucuyener, A. Montero-Calle, R. Barderas, J. M. Pingarrón, S. Campuzano, S. A. Ozkan. Talanta, 246 (2022) 123526.
First magnetic beads-based immunosensor for GFAP determination.
Amperometric detection at screen-printed carbon electrodes.
Sensitivity (LOD of 67 pg mL−1) and selectivity compatible with clinical applicability.
Discrimination of patients with Alzheimer's disease by analyzing brain extracts.
GFAP
Immunoplatform
Alzheimer disease
MBs
Brain tissue extracts
Open Access – Paving the Way for Reliable Alzheimer’s Disease Blood Diagnosis by Quadruple Electrochemical Immunosensing
A. Valverde, J.M. Gordón Pidal, A. Montero-Calle, B. Arévalo, V. Serafín, M. Calero, M. Moreno-Guzmán, M.A. López, A. Escarpa, P. Yáñez-Sedeño, R. Barderas, S. Campuzano, J.M. Pingarrón. ChemElectroChem, 9, 9 (2022) 202200055.
A quadruple immunoplatform for the amperometric determination of AD-candidate protein blood biomarkers (neurofilament light chain, NfL, Tau, phosphorylated Tau, p-Tau and TAR DNA-Binding Protein 43, TDP-43) to assist in the reliable and minimally invasive Alzheimer's disease diagnosis was developed.
Alzheimer´s disease
Candidate biomarkers
Electrochemical multiplexing immunoplatform
Magnetic microbeads
Plasma
A. Valverde, A. Montero-Calle, B. Arévalo, P. San Segundo-Acosta, V. Serafín, M. Alonso-Navarro, G. Solís-Fernández, J. M. Pingarrón, S. Campuzano and R. Barderas. Analysis & Sensing, 1, 4 (2021), 161-165.
An electrochemical biosensing platform for serum autoantibodies (AAbs) detection is reported in this work, exploiting for the first time six Alzheimer's disease (AD)-specific phage-derived and frameshift aberrant HaloTag peptides as receptors, immobilized on magnetic microbeads (MBs) surface and captured on disposable electrodes to perform amperometric detection. Operational analytical characteristics and clinical diagnostic ability of the bioplatform were probed in optimized key experimental conditions by analysing serum AAbs of AD patients and healthy subjects.
Alzheimer’s disease
Autoantibodies
Electrochemical biosensors
Phage-derived peptides
Receptors
A. Valverde, A. Montero-Calle, R. Barderas, M. Calero, P. Yáñez-Sedeño, S. Campuzano, J.M. Pingarrón. Electrochimica Acta, 371 (2021) 137815.
Alzheimer's disease (AD) is a common neurodegenerative disorder associated with massive degradation of neuronal cell structure due to aging. In recent years, neurofilament light chain (NfL) arises as one of the most promising blood biomarkers for AD. Bioassays available for NfL determination in blood (ELISA kits or Simoa assays) require multiple steps, specialized personnel and expensive instrumentation of application limited to centralized and high-resource environments. With the aim of overcoming these drawbacks, this work reports the first magnetic microbeads (MBs)-based electrochemical bioplatform developed so far for the determination of NfL.
C.A. Razzino, V. Serafín, M. Gamella, M. Pedrero, A. Montero-Calle, R. Barderas, M. Calero, A.O. Lobo, P. Yañez-Sedeño, S. Campuzano, J.M. Pingarron. Biosensors & Bioelectronics, 163 (2020) 112238.
This work reports a new sensitive strategy for the determination of tau protein, a hallmark of Alzheimer's disease (AD), involving a sandwich immunoassay and amperometric detection at disposable screen-printed carbon electrodes (SPCEs) modified with a gold nanoparticles-poly(amidoamine) (PAMAM) dendrimer nanocomposite (3D-Au-PAMAM) covalently immobilized onto electrografted p-aminobenzoic acid (p-ABA). The great analytical performance of the immunosensor in terms of selectivity and low limit of detection (LOD) (1.7 pg mL−1) allowed the direct determination of the target protein in raw plasma samples and in brain tissue extracts from healthy individuals and post mortem diagnosed AD patients, using a simple and fast protocol.
Serafín, M. Gamella, M. Pedrero, A. Montero-Calle, C.A. Razzino, P. Yáñez-Sedeño, R. Barderas, S. Campuzano, J.M. Pingarrón. Journal of Pharmaceutical and Biomedical Analysis, 189 (2020) 113437.
Neurodegenerative disorders (NDD), and particularly Alzheimer's disease (AD), are one of the greatest challenges facing our current medicine and society because of its increasing incidence and the high burden imposed both on patients’ families and health systems. Despite this, their accurate diagnosis, mostly conducted by cerebrospinal fluid (CSF) analysis or neuroimaging techniques, costly, time-consuming, and unaffordable for most of the population, remains a complex task. In this situation, electrochemical biosensors are flourishing as promising alternative tools for the simple, fast, and low-cost diagnosis of NDD/AD.